Hansen Medical to Present at the 31st Annual J.P. Morgan

Hansen Medical to Present at the 31st Annual J.P. Morgan Healthcare
MOUNTAIN VIEW, CA -- (Marketwire) -- 12/27/12 --  Hansen Medical,
Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today
announced that President and CEO Bruce Barclay is scheduled to
present at the 31st Annual J.P. Morgan Healthcare Conference. The
conference is being held January 7-10, 2013 at the Westin St. Francis
Hotel in San Francisco, California. Hansen Medical is scheduled to
present on Thursday, January 10, 2013 at 11:30 a.m. Pacific Time.  
Hansen Medical will provide a live webcast of the audio presentation.
Interested parties may access the live webcast by visiting the
investor relations section of Hansen Medical's web site at
www.hansenmedical.com. A replay of the webcast will be available at
the site after the presentation.  
About Hansen Medical, Inc. 
 Hansen Medical, Inc., based in Mountain
View, California, is the global leader in intravascular robotics,
developing products and technology designed to enable the accurate
positioning, manipulation and control of catheters and catheter-based
technologies. The Company's Magellan(TM) Robotic System,
NorthStar(TM) Robotic Catheter and related accessories, which are
intended to facilitate navigation to anatomical targets in the
peripheral vasculature and subsequently provide a conduit for manual
placement of therapeutic devices, have undergone both CE marking and
510(k) clearance and are commercially available in the European
Union, and the U.S. In the European Union, the Company's Sensei(R) X
Robotic Catheter System and Artisan Control Catheter are cleared for
use during electrophysiology (EP) procedures, such as guiding
catheters in the treatment of atrial fibrillation (AF), and the
Lynx(R) Robotic Ablation Catheter is cleared for the treatment of AF.
This robotic catheter system is compatible with fluoroscopy,
ultrasound, 3D surface map and patient electrocardiogram data. In the
U.S. the Company's Sensei X Robotic Catheter System and Artisan
Control Catheter were cleared by the U.S. Food and Drug
Administration for manipulation and control of certain mapping
catheters in EP procedures. In the United States, the Sensei System
is not approved for use in guiding ablation procedures; this use
remains exp
erimental. The U.S. product labeling therefore provides
that the safety and effectiveness of the Sensei X System and Artisan
Control Catheter for use with cardiac ablation catheters in the
treatment of cardiac arrhythmias, including AF, have not been
established. Additional information can be found at
Forward-Looking Statements
 This press release contains
forward-looking statements regarding, among other things, statements
relating to goals, plans, objectives, milestones and future events.
All statements, other than statements of historical fact, are
statements that could be deemed forward-looking statements, including
statements containing the words "plan," "expects," "potential,"
"believes," "goal," "estimate," "anticipates," and similar words.
These statements are based on the current estimates and assumptions
of our management as of the date of this press release and are
subject to risks, uncertainties, changes in circumstances and other
factors that may cause actual results to differ materially from the
information expressed or implied by forward-looking statements made
in this press release. Examples of such statements include statements
about the potential benefits of our technology and the value of our
intellectual property portfolio. Important factors that could cause
actual results to differ materially from those indicated by such
forward-looking statements include, among others: engineering,
regulatory, manufacturing, sales and customer service challenges in
developing new products and entering new markets; potential safety
and regulatory issues that could slow or suspend our sales; the
effect of credit, financial and economic conditions on capital
spending by our potential customers; the uncertain timelines for the
sales cycle for newly introduced products; the rate of adoption of
our systems and the rate of use of our catheters; the scope and
validity of intellectual property rights applicable to our products;
competition from other companies; our ability to recruit and retain
key personnel; our ability to maintain our remedial actions over
previously reported material weaknesses in internal controls over
financial reporting; our ability to manage expenses and cash flow,
and obtain additional financing; and other risks more fully described
in the "Risk Factors" section of our Quarterly Report on Form 10-Q
for the quarter ended September 30, 2012 filed with the SEC on
November 9, 2012 and the risks discussed in our other reports filed
with the SEC. Given these uncertainties, you should not place undue
reliance on the forward-looking statements in this press release. We
undertake no obligation to revise or update information herein to
reflect events or circumstances in the future, even if new
information becomes available.  
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart
Design), Sensei and Lynx are registered trademarks, and Magellan and
NorthStar are trademarks of Hansen Medical, Inc. in the United States
and other countries. 
Investor Contacts: 
Peter J. Mariani 
Chief Financial Officer 
Hansen Medical, Inc. 
FTI Consulting, Inc.
Brian Ritchie
John Capodanno
Press spacebar to pause and continue. Press esc to stop.